Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Incyte Corporation
Mayo Clinic
Fate Therapeutics
MEI Pharma, Inc.
Brown University
Alliance for Clinical Trials in Oncology
Swiss Cancer Institute
Wake Forest University Health Sciences
Aptevo Therapeutics
Case Comprehensive Cancer Center
City of Hope Medical Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
Mayo Clinic